Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, September 2006, p. 3222-3224, Vol. 50, No. 9
0066-4804/06/$08.00+0 doi:10.1128/AAC.00284-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Emergence of PER-2 and VEB-1a in Acinetobacter baumannii Strains in the Americas

LETTER
Antimicrobial treatment of
Acinetobacter infections may be limited
because of the emergence of extended-spectrum ß-lactamase
(ESBL)- and carbapenemase-producing multiresistant strains (
7,
13). Non-TEM-, non-SHV-derived ESBLs (such as PER and VEB) have
been documented in
Acinetobacter isolates from Europe and Asia
(
7) but not yet from the Americas.
Recently, an increasing trend has been documented in carbapenem and extended-spectrum cephalosporin resistance in Acinetobacter isolates in Buenos Aires. Indeed, data from the Whonet-Argentina Network showed that, in 2004, more than 80% of Acinetobacter isolates were resistant to extended-spectrum cephalosporins. In addition, imipenem resistance increased from 5% to 54%, in the period from 2000 to 2004 (M. Galas, unpublished results). National ESBL surveillance is performed by Whonet-Argentina Network participants using a modification of the CLSI antibiogram (8), consisting of a synergy test with ceftazidime or cefepime and amoxicillin-clavulanic acid (distance between disks, 20 mm, center to center).
FAV-1 and M5179 were the first putative ESBL-producing Acinetobacter baumannii strains isolated at two hospitals in Buenos Aires in 2000 and 2003, respectively. FAV-1 was a colonizer from the urine of a patient hospitalized for lung transplantation. M5179 was from the peritoneal fluid of a patient with hemolytic-uremic syndrome. Strains were confirmed to be A. baumannii by using the API 20NE system (bioMérieux, Marcy l'Etoile, France) combined with their ability to grow at 44°C.
MICs (micrograms per milliliter) for FAV-1 and M5179 determined by agar dilution (10) were, respectively, as follows: ticarcillin, 1,024 and 1,024; piperacillin, 512 and 256; piperacillin-tazobactam, 512 and 0.5; ampicillin-sulbactam, 8 and 8; cefotaxime, 64 and 64; cefotaxime-clavulanate, 64 and 8; ceftazidime, 64 and 512; ceftazidime-clavulanate, 16 and 2; cefepime, 64 and 64; cefepime-clavulanate, 16 and 4; aztreonam, 512 and 512; imipenem, 8 and 0.5; meropenem, 8 and 0.5; amikacin, 128 and 32; gentamicin, 2 and 32; trimethoprim-sulfamethoxazole, 128 and 8; ciprofloxacin, 32 and 0.12; rifampin, 2 and >32; minocycline, 0.5 and <0.25. EDTA (0.4 mM) did not affect carbapenem MICs.
Attempts to transfer the ceftazidime (FAV-1 and M5179) or imipenem (FAV-1) resistance marker by conjugation or electroporation to Escherichia coli ER1793 (6) were unsuccessful.
Isoelectric focusing analysis (6) revealed ESBL bands at pIs of 5.4 (FAV-1) and 7.4 (M5179) and narrow-spectrum ß-lactamase bands at pIs of 6.9, 9.4 (FAV-1), and 5.4 (M5179). A band at a pI of 9.4 was inhibited by oxacillin (1 mM) (probable AmpC-like enzyme). A band at a pI of 6.9 showed weak activity against imipenem and was not inhibited by oxacillin, clavulanate (1 mM), or EDTA (30 mM).
In the PCR screening for ESBL genes (Table 1), amplifications of blaPER (FAV-1) or blaTEM and blaVEB (M5179) were positive. DNA sequencing identified the genes as blaPER-2, blaTEM-1, and blaVEB-1a (11) (the latter unequivocally identified by full-length amplification and sequencing). PCR mapping with class 1 integron-blaVEB primer combinations (5'-CS-VEB-R, IntI1-F-VEB-R, VEB-F-3'-CS, and VEB-F-sulI-R) under either conventional or long amplification (Elongase Amplification System, Invitrogen, California) conditions yielded negative results. A PCR assay with primers 5'-CS and 3'-CS resulted in a unique amplicon of 1,395 bp that carried arr-2 (first report in Argentina) and aacA4 cassettes (4). PCRs with primers targeting intI2 and intI3 or with primer combinations 3'-CS-VEB-R, 3'-CS-VEB-Rc, sulI-R-VEB-R, and sulI-R-VEB-Rc, to target antisense insertion of blaVEB-1a (1), also failed to generate amplicons. These data suggested an unusual localization of the blaVEB-1a gene in M5179.
The PCR characterization of the carbapenemase-encoding genes
in FAV-1 (Table
1) yielded positive amplifications for
blaOXA subgroup 3 and
blaOXA-58. The identities of
blaOXA-51 and
blaOXA-58 were determined by amplification and sequencing of complete
genes and flanking regions as described previously (
2) (GenBank
accession numbers DQ385606 and DQ385607, respectively). The
region upstream of
blaOXA-51 showed 79% identity with a fragment
of the
Acinetobacter sp. strain ADP1 genome (positions 2,028,863
to 2,029,156 in the sequence with GenBank accession number CR543861),
supporting its previously proposed chromosomal location (
3).
The genetic environment of
blaOXA-58 was the same as that in
an
A. baumannii isolate from France, i.e., bracketed by two
IS
Aba3 elements in opposite orientations (
10).
This is the first report of VEB- and PER-producing Acinetobacter strains in the Americas and also the first documentation of a VEB-type enzyme on this continent. Since 2003, a nationwide surveillance effort to address the degree of dissemination of ESBLs among Acinetobacter strains in Argentina has revealed the occurrence of 21 ESBL-producing isolates, PER-2 (n = 11) and VEB (n = 10), in four provinces. Therefore, the emergence of both VEB and PER-2 in Acinetobacter strains in Argentina constitutes a public health concern.

ACKNOWLEDGMENTS
Fernando Pasterán and Melina Rapoport contributed equally
to this work.

REFERENCES
1 - Aubert, D., D. Girlich, T. Naas, S. Nagarajan, and P. Nordmann. 2004. Functional and structural characterization of the genetic environment of an extended-spectrum ß-lactamase blaVEB gene from a Pseudomonas aeruginosa isolate obtained in India. Antimicrob. Agents Chemother. 48:3284-3290.[Abstract/Free Full Text]
2 - Brown, S., H. Young, and S. G. Amyes. 2005. Characterisation of OXA-51, a novel class D carbapenemase found in genetically unrelated clinical strains of Acinetobacter baumannii from Argentina. Clin. Microbiol. Infect. 11:15-23.[Medline]
3 - Héritier, C., L. Poirel, P. E. Fournier, J. M. Claverie, D. Raoult, and P. Nordmann. 2005. Characterization of the naturally occurring oxacillinase of Acinetobacter baumannii. Antimicrob. Agents Chemother. 49:4174-4179.[Abstract/Free Full Text]
4 - Houang, E., Y. W. Chu, W. S. Lo, K. Y. Chu, and A. F. Cheng. 2003. Epidemiology of rifampin ADP-ribosyltransferase (arr-2) and metallo-ß-lactamase (blaIMP-4) gene cassettes in class 1 integrons in Acinetobacter strains isolated from blood cultures in 1997 to 2000. Antimicrob. Agents Chemother. 47:1382-1390.[Abstract/Free Full Text]
5 - Levesque, C., L. Piche, C. Larose, and P. H. Roy. 1995. PCR mapping of integrons reveals several novel combinations of resistance genes. Antimicrob. Agents Chemother. 39:185-191.[Abstract]
6 - Melano, R., A. Corso, A. Petroni, D. Centrón, B. Orman, A. Pereyra, N. Moreno, and M. Galas. 2003. Multiple antibiotic-resistance mechanisms including a novel combination of extended-spectrum ß-lactamases in a Klebsiella pneumoniae clinical strain isolated in Argentina. J. Antimicrob. Chemother. 52:36-42.[Abstract/Free Full Text]
7 - Naas, T., P. Bogaerts, C. Bauraing, Y. Degheldre, Y. Glupczynski, and P. Nordmann. 2006. Emergence of PER and VEB extended-spectrum ß-lactamases in Acinetobacter baumannii in Belgium. J. Antimicrob. Chemother. 0:dkl178v1. [Epub ahead of print.]
8 - National Committee for Clinical Laboratory Standards. 2003. Performance standards for antimicrobial disk susceptibility test, 8th ed. Approved standard M2-A8. National Committee for Clinical Laboratory Standards, Wayne, Pa.
9 - Pasteran, F., D. Faccone, A. Petroni, M. Rapoport, M. Galas, M. Vazquez, and A. Procopio. 2005. Novel variant (blaVIM-11) of the metallo-ß-lactamase blaVIM family in a GES-1 extended-spectrum-ß-lactamase-producing Pseudomonas aeruginosa clinical isolate in Argentina. Antimicrob. Agents Chemother. 49:474-475.[Free Full Text]
10 - Poirel, L., S. Marque, C. Héritier, C. Segonds, G. Chabanon, and P. Nordmann. 2005. OXA-58, a novel class D ß-lactamase involved in resistance to carbapenems in Acinetobacter baumannii. Antimicrob. Agents Chemother. 49:202-208.[Abstract/Free Full Text]
11 - Poirel, L., O. Menuteau, N. Agoli, C. Cattoen, and P. Nordmann. 2003. Outbreak of extended-spectrum ß-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a French hospital. J. Clin. Microbiol. 41:3542-3547.[Abstract/Free Full Text]
12 - Reyes, A., H. Bello, M. Domínguez, S. Mella, R. Zemelman, and G. González. 2003. Prevalence and types of class 1 integrons in aminoglycoside-resistant Enterobacteriaceae from several Chilean hospitals. J. Antimicrob. Chemother. 51:317-321.[Abstract/Free Full Text]
13 - Walther-Rasmussen, J., and N. Høiby. 2006. OXA-type carbapenemases. J. Antimicrob. Chemother. 57:373-383.[Abstract/Free Full Text]
| | | | | |
Fernando Pasterán
Melina Rapoport
Alejandro Petroni
Diego Faccone
Alejandra Corso
Marcelo Galas*
Servicio Antimicrobianos Departamento Bacteriología Instituto Nacional de Enfermedades Infecciosas-ANLIS "Carlos G. Malbrán" Ciudad Autónoma de Buenos Aires, Argentina,1
Miryam Vázquez
Adriana Procopio
Sección Microbiología Hospital de Niños "Ricardo Gutiérrez" Gobierno de Buenos Aires Ciudad Autónoma de Buenos Aires, Argentina,2
Marta Tokumoto
Viviana Cagnoni
Instituto de Cardiología y Cirugía Cardiovascular "Fundación Favaloro" Ciudad Autónoma de Buenos Aires, Argentina,3
|
| | | | | |
* Phone and fax: 54 11 4 303 2812, E-mail: mgalas{at}anlis.gov.ar |
Antimicrobial Agents and Chemotherapy, September 2006, p. 3222-3224, Vol. 50, No. 9
0066-4804/06/$08.00+0 doi:10.1128/AAC.00284-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Poirel, L., Mugnier, P. D., Toleman, M. A., Walsh, T. R., Rapoport, M. J., Petroni, A., Nordmann, P.
(2009). ISCR2, Another Vehicle for blaVEB Gene Acquisition. Antimicrob. Agents Chemother.
53: 4940-4943
[Abstract]
[Full Text]
-
Pasteran, F., Mendez, T., Guerriero, L., Rapoport, M., Corso, A.
(2009). Sensitive Screening Tests for Suspected Class A Carbapenemase Production in Species of Enterobacteriaceae. J. Clin. Microbiol.
47: 1631-1639
[Abstract]
[Full Text]
-
Zong, Z., Partridge, S. R., Iredell, J. R.
(2009). A blaVEB-1 Variant, blaVEB-6, Associated with Repeated Elements in a Complex Genetic Structure. Antimicrob. Agents Chemother.
53: 1693-1697
[Abstract]
[Full Text]
-
Curcio, D., Fernandez, F.
(2008). Comment on: Effect of different Mueller-Hinton agars on tigecycline disc diffusion susceptibility for Acinetobacter spp.. J Antimicrob Chemother
62: 1166-1167
[Full Text]
-
Curcio, D.
(2008). Comment: Tigecycline for the Treatment of Acinetobacter Infections: A Case Series. The Annals of Pharmacotherapy
42: 1717-1718
[Full Text]
-
Marchiaro, P., Ballerini, V., Spalding, T., Cera, G., Mussi, M. A., Moran-Barrio, J., Vila, A. J., Viale, A. M., Limansky, A. S.
(2008). A convenient microbiological assay employing cell-free extracts for the rapid characterization of Gram-negative carbapenemase producers. J Antimicrob Chemother
62: 336-344
[Abstract]
[Full Text]
-
Kiratisin, P., Apisarnthanarak, A., Laesripa, C., Saifon, P.
(2008). Molecular Characterization and Epidemiology of Extended-Spectrum- {beta}-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Isolates Causing Health Care-Associated Infection in Thailand, Where the CTX-M Family Is Endemic. Antimicrob. Agents Chemother.
52: 2818-2824
[Abstract]
[Full Text]
-
Peleg, A. Y., Seifert, H., Paterson, D. L.
(2008). Acinetobacter baumannii: Emergence of a Successful Pathogen. Clin. Microbiol. Rev.
21: 538-582
[Abstract]
[Full Text]
-
Curcio, D., Fernandez, F.
(2007). Acinetobacter spp. susceptibility to tigecycline: a worldwide perspective. J Antimicrob Chemother
60: 449-450
[Full Text]
-
Power, P., Di Conza, J., Rodriguez, M. M., Ghiglione, B., Ayala, J. A., Casellas, J. M., Radice, M., Gutkind, G.
(2007). Biochemical Characterization of PER-2 and Genetic Environment of blaPER-2. Antimicrob. Agents Chemother.
51: 2359-2365
[Abstract]
[Full Text]
-
Curcio, D., Fernandez, F., Jones, R. N., Ferraro, M. J., Reller, L. B., Schreckenberger, P. C., Sader, H. S.
(2007). Tigecycline Disk Diffusion Breakpoints of Acinetobacter spp.: a Clinical Point of View. J. Clin. Microbiol.
45: 2095-2096
[Full Text]
-
Endimiani, A., Luzzaro, F., Migliavacca, R., Mantengoli, E., Hujer, A. M., Hujer, K. M., Pagani, L., Bonomo, R. A., Rossolini, G. M., Toniolo, A.
(2007). Spread in an Italian Hospital of a Clonal Acinetobacter baumannii Strain Producing the TEM-92 Extended-Spectrum {beta}-Lactamase. Antimicrob. Agents Chemother.
51: 2211-2214
[Abstract]
[Full Text]
-
Poirel, L., Corvec, S., Rapoport, M., Mugnier, P., Petroni, A., Pasteran, F., Faccone, D., Galas, M., Drugeon, H., Cattoir, V., Nordmann, P.
(2007). Identification of the Novel Narrow-Spectrum {beta}-Lactamase SCO-1 in Acinetobacter spp. from Argentina. Antimicrob. Agents Chemother.
51: 2179-2184
[Abstract]
[Full Text]